tiprankstipranks
Advertisement
Advertisement
Alterity Therapeutics Files June 2026 Form 6-K Highlighting Changes in Directors’ Interests
PremiumCompany AnnouncementsAlterity Therapeutics Files June 2026 Form 6-K Highlighting Changes in Directors’ Interests
24d ago
Alterity Therapeutics assumed with a Buy at Ladenburg
Premium
The Fly
Alterity Therapeutics assumed with a Buy at Ladenburg
25d ago
Alterity Therapeutics Files June 2026 Corporate Presentation With U.S. Regulator
Premium
Company Announcements
Alterity Therapeutics Files June 2026 Corporate Presentation With U.S. Regulator
25d ago
Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
PremiumCompany AnnouncementsAlterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
1M ago
Alterity Therapeutics management to meet with BTIG
Premium
The Fly
Alterity Therapeutics management to meet with BTIG
1M ago
Alterity Therapeutics Data Underpin Phase 3 Advancement of ATH434 in Multiple System Atrophy
Premium
Company Announcements
Alterity Therapeutics Data Underpin Phase 3 Advancement of ATH434 in Multiple System Atrophy
2M ago
Alterity Therapeutics presents new data analyses from ATH434 trial
PremiumThe FlyAlterity Therapeutics presents new data analyses from ATH434 trial
3M ago
Alterity Therapeutics appoints Cunningham to Board of Directors
Premium
The Fly
Alterity Therapeutics appoints Cunningham to Board of Directors
3M ago
Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434
Premium
The Fly
Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100